Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently amended) A compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a monocyclic heteroaromatic ring selected from the group consisting of thiophene, furan, pyrrole, pyridine, ~~pryimidine~~pyrimidine, pyridazine, and pyrazine;

R^1 is H, OH, OC_{1-3}alkyl, C_{1-3}alkyl, C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $CONR^5R^6$, $S(=O)_mC_{1-3}$alkyl, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl; with the proviso that if Aryl is thiophene, then $R^2 \neq$H or halo, and $R^1 \neq$OH;

R^3, R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, where R^5 and R^6 optionally can be joined together to form a pyrrolidine or piperidine ring which can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt ~~or solvate~~ thereof.

2 - 4. (Cancelled)

5. (Currently amended) A method for lowering IOP which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring selected from the group consisting of thiophene, furan, pyrrole, pyridine, ~~pryimidine~~pyrimidine, pyridazine, and pyrazine;

R^1 is H, OH, OC_{1-3}alkyl, C_{1-3}alkyl, C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $CONR^5R^6$, $S(=O)_mC_{1-3}$alkyl, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^3, R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, where R^5 and R^6 optionally can be joined together to form a pyrrolidine or piperidine ring which can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt ~~or solvate~~ thereof.

6. (Currently amended) A method for lowering IOP which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring selected from the group consisting of thiophene, furan, pyrrole, pyridine, ~~pryimidine~~pyrimidine, pyridazine, and pyrazine;

R^1 is H, C_{1-5}alkyl, C_{3-5}alkenyl, an aromatic ring selected from the group consisting of phenyl, thienyl, pyridyl, and imidazoyl which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, or CF_3; or C_{2-5}alkyl substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl or an aromatic ring selected from the group consisting of phenyl, thienyl, pyridyl, and imidazoyl, which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, CF_3, $S(=O)_2$ NR^5R^6; or C_{3-5}alkenyl substituted optionally with OH, OC_{1-3}alkyl, or $S(=O)_mC_{1-3}$alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, $S(=O)_2$ NR^5R^6, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^3 & R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, where R^5 and R^6 optionally can be joined together to form a pyrrolidine or piperidine ring which can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or

substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt ~~or solvate~~ thereof.

7. (Cancelled)

8. (Cancelled)

9. (Currently Amended) A method for improving blood flow to the optic nerve head and the retina which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a monocyclic heteroaromatic ring selected from the group consisting of thiophene, furan, pyrrole, pyridine, ~~pryimidine~~pyrimidine, pyridazine, and pyrazine;

R^1 is H, OH, OC_{1-3}alkyl, C_{1-3}alkyl, C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $CONR^5R^6$, $S(=O)_mC_{1-3}$alkyl, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl; with the proviso that if Aryl is thiophene, then $R^2 \neq$H or halo, and $R^1 \neq$OH;

R^3, R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, where R^5 and R^6 optionally can be joined together to form a pyrrolidine or piperidine

ring which can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt ~~or solvate~~ thereof.

10. (Currently Amended) A method for improving blood flow to the optic nerve head and the retina which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring selected from the group consisting of thiophene, furan, pyrrole, pyridine, ~~pryimidine~~pyrimidine, pyridazine, and pyrazine;

R^1 is H, C_{1-5}alkyl, C_{3-5}alkenyl, an aromatic ring selected from the group consisting of phenyl, thienyl, pyridyl, and imidazoyl which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, or CF_3; or C_{2-5}alkyl substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl or an aromatic ring selected from the group consisting of phenyl, thienyl, pyridyl, and imidazoyl, which is either unsubstituted or substituted

optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, CF_3, $S(=O)_2$ NR^5R^6; or C_{3-5}alkenyl substituted optionally with OH, OC_{1-3}alkyl, or $S(=O)_mC_{1-3}$alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, $S(=O)_2$ NR^5R^6, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^3 & R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, where R^5 and R^6 optionally can be joined together to form a pyrrolidine or piperidine ring which can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt ~~or solvate~~ thereof.

11. (Cancelled)

12. (Cancelled)

13. (Currently amended) A method for treating retinal diseases selected from the group consisting of glaucoma, age related macular degeneration (ARMD), optic neuritis, ischemic disorders, diabetic retinopathy, and retinal edema which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a monocyclic heteroaromatic ring selected from the group consisting of thiophene, furan, pyrrole, pyridine, ~~pryimidine~~pyrimidine, pyridazine, and pyrazine;

R^1 is H, OH, OC_{1-3}alkyl, C_{1-3}alkyl, C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $CONR^5R^6$, $S(=O)_mC_{1-3}$alkyl, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl; with the proviso that if Aryl is thiophene, then $R^2 \neq$H or halo, and $R^1 \neq$OH;

R^3, R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, where R^5 and R^6 optionally can be joined together to form a pyrrolidine or piperidine ring which can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt ~~or solvate~~ thereof.

14. (Currently amended) A method for treating retinal diseases selected from the group consisting of glaucoma, age related macular degeneration (ARMD), optic neuritis, ischemic disorders, diabetic retinopathy, and retinal edema which

comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring selected from the group consisting of thiophene, furan, pyrrole, pyridine, ~~pryimidine~~pyrimidine, pyridazine, and pyrazine;

R^1 is H, C_{1-5}alkyl, C_{3-5}alkenyl, an aromatic ring selected from the group consisting of phenyl, thienyl, pyridyl, and imidazoyl which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, or CF_3; or C_{2-5}alkyl substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl or an aromatic ring selected from the group consisting of phenyl, thienyl, pyridyl, and imidazoyl, which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, CF_3, $S(=O)_2$ NR^5R^6; or C_{3-5}alkenyl substituted optionally with OH, OC_{1-3}alkyl, or $S(=O)_mC_{1-3}$alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, $S(=O)_2$ NR^5R^6, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^3 & R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, where R^5 and R^6 optionally can be joined together to form a pyrrolidine or piperidine ring which can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or

substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt ~~or solvate~~ thereof.

15 – 38. (Cancelled)

39. (Currently Amended) A method for treating persons suffering from a sleeping disorder, depression, schizophrenia, anxiety, circadian rhythm disorders, and centrally and peripherally mediated hypertension, which comprises, administering a composition comprising a pharmaceutically effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a monocyclic heteroaromatic ring selected from the group consisting of thiophene, furan, pyrrole, pyridine, ~~pryimidine~~pyrimidine, pyridazine, and pyrazine;

R^1 is H, OH, OC_{1-3}alkyl, C_{1-3}alkyl, C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $CONR^5R^6$, $S(=O)_mC_{1-3}$alkyl, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl; with the proviso that if Aryl is thiophene, then $R^2 \neq$H or halo, and $R^1 \neq$OH;

R^3, R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, where R^5 and R^6 optionally can be joined together to form a pyrrolidine or piperidine ring which can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt ~~or solvate~~ thereof.

40. (Currently amended) A method for treating persons suffering from a sleeping disorder, depression, schizophrenia, anxiety, obsessive compulsive disorder, circadian rhythem disorders, and centrally and peripherally mediated hypertension which comprises, administering a composition comprising a pharmaceutically effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring selected from the group consisting of thiophene, furan, pyrrole, pyridine, ~~pryimidine~~pyrimidine, pyridazine, and pyrazine;

R^1 is H, C_{1-5}alkyl, C_{3-5}alkenyl, an aromatic ring selected from the group consisting of phenyl, thienyl, pyridyl, and imidazoyl which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, or CF_3; or C_{2-5}alkyl substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl or an aromatic ring selected from the group consisting of phenyl, thienyl, pyridyl, and imidazoyl, which is either unsubstituted or substituted

optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, CF_3, $S(=O)_2$ NR^5R^6; or C_{3-5}alkenyl substituted optionally with OH, OC_{1-3}alkyl, or $S(=O)_mC_{1-3}$alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, $S(=O)_2$ NR^5R^6, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^3 & R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, where R^5 and R^6 optionally can be joined together to form a pyrrolidine or piperidine ring which can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt ~~or solvate~~ thereof.

41. (Cancelled)

42. (Cancelled)

43. (Currently amended) A composition comprising a pharmaceutically effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a monocyclic heteroaromatic ring selected from the group consisting of thiophene, furan, pyrrole, pyridine, ~~pryimidine~~pyrimidine, pyridazine, and pyrazine;

R^1 is H, OH, OC_{1-3}alkyl, C_{1-3}alkyl, C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $CONR^5R^6$, $S(=O)_mC_{1-3}$alkyl, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl; with the proviso that if Aryl is thiophene, then $R^2 \neq$H or halo, and $R^1 \neq$OH;

R^3, R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, where R^5 and R^6 optionally can be joined together to form a pyrrolidine or piperidine ring which can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt ~~or solvate~~ thereof in a pharmaceutically acceptable carrier.

44. (Currently amended) A composition comprising a pharmaceutically effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring selected from the group consisting of thiophene, furan, pyrrole, pyridine, ~~pryimidine~~pyrimidine, pyridazine, and pyrazine;

R^1 is H, C_{1-5}alkyl, C_{3-5}alkenyl, an aromatic ring selected from the group consisting of phenyl, thienyl, pyridyl, and imidazoyl which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, or CF_3; or C_{2-5}alkyl substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl or an aromatic ring selected from the group consisting of phenyl, thienyl, pyridyl, and imidazoyl, which is either unsubstituted or substituted optionally with OH, OC_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, halogen, CF_3, $S(=O)_2$ NR^5R^6; or C_{3-5}alkenyl substituted optionally with OH, OC_{1-3}alkyl, or $S(=O)_mC_{1-3}$alkyl;

R^2 is H, halogen, C_{1-3}alkyl, $S(=O)_mC_{1-3}$alkyl, $S(=O)_2$ NR^5R^6, or C_{1-3}alkyl substituted optionally with OH, or OC_{1-3}alkyl;

R^3 & R^4 are independently H, C_{1-3}alkyl, or C_{1-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^5, R^6 are independently H, C_{1-3}alkyl, or C_{2-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, where R^5 and R^6 optionally can be joined together to form a pyrrolidine or piperidine ring which can be either unsubstituted or substituted optionally with C_{1-3}alkyl, C_{2-3}alkyl substituted optionally with OH or OC_{1-3}alkyl;

R^7, R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ^3-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3}alkyl, C_{1-3}alkyl substituted optionally with OH, OC_{1-3}alkyl, or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl, or substituted on nitrogen with C_{1-4}alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3, OC_{1-3}alkyl, or C_{1-3}alkyl;

n is 2 to 4;

m is 0, 1 or 2

or a pharmaceutically acceptable salt ~~or solvate~~ thereof in a pharmaceutically acceptable carrier.

45. (Cancelled)

46. (Cancelled)

47. (Original) The Compound of Claim 1 selected from the group consisting of:

6-Chloro-2-[4-[4-(2*H*-benzimidazo-2-oxo-1-yl)piperidin-1-yl]butyl]-2*H*-thieno[3,2-*e*]-1,2-thiazine 1,1-dioxide;

6-Chloro-2-[4-(4-phenylpiperazin-1-yl)butyl]-2*H*-thieno[3,2-*e*]-1,2-thiazine 1,1-dioxide;

6-Chloro-2-[4-[4-(2-fluorophenyl)piperazin-1-yl]butyl]-2*H*-thieno[3,2-*e*]-1,2-thiazine 1,1-dioxide;

6-Chloro-2-[3-[4-(3-trifluoromethylphenyl)piperazin-1-yl]propyl]-2*H*-thieno[3,2-*e*]-1,2-thiazine 1,1-dioxide;

6-Chloro-2-[3-[4-(2*H*-benzimidazol-2-oxo)piperidin-1-yl]propyl]-2*H*-thieno[3,2-*e*]-1,2-thiazine 1,1-dioxide.

48. (Cancelled)

49. (Cancelled)